ARTICLE | Clinical News

Mipsagargin: Phase II data

January 26, 2015 8:00 AM UTC

An open-label, U.S. Phase II trial in 20 evaluable HCC patients who had previously progressed on or who were intolerant of Nexavar sorafenib showed that 40 mg/m 2 IV mipsagargin on days 1-3 of each 2...